SVB Securities analyst Mani Foroohar downgraded Graphite Bio to Market Perform from Outperform with a price target of $2, down from $11.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GRPH:
- Graphite Bio downgraded to Market Perform from Outperform at BMO Capital
- Graphite Bio to voluntarily pause Phase 1/2 CEDAR study
- Graphite Bio price target lowered to $8 from $10 at BofA
- 2 “Strong Buy” Penny Stocks That Could See 200% Gains (Or More)
- Graphite Bio reports Q3 EPS (45c), consensus (46c)